- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01216007
A Pilot Study to Investigate Plasma Bupivacaine Concentrations in Children Receiving Total Intravenous Anaesthesia and Caudal Analgesia
Study Overview
Detailed Description
Hypothesis:
The investigators hypothesize that there will be a detectable difference in free plasma [bupivacaine] between these two treatment groups, with lower free plasma [bupivacaine] in the TIVA group.
Background:
Local anesthetics (LA) are frequently administered intra-operatively, in combination with general anaesthesia, for pain management in children. Although highly effective in this regard, LAs possess a narrow margin of safety. High plasma levels can cause toxicity in both the central nervous system (CNS) and the cardiovascular system (CVS) and may result from either the correct placement of an excessive dose or an inadvertent intravenous (IV) injection of a correct dose.
Specific Objectives:
The objective of this pilot study is to compare plasma [bupivacaine] between two groups of paediatric patients under general anaesthesia who will all receive regional caudal anaesthesia with bupivacaine: group 1 will receive TIVA and group 2 will receive a volatile anaesthetic.
Methods:
Induction of anesthesia: The TIVA group will receive the BCCH standard regimen comprising induction with propofol 5 mg/kg and remifentanil 2.5 mcg/kg, followed by maintenance infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Total cumulative Intralipid® doses will be recorded at times of caudal injection and blood sampling. The volatile anesthesia group will undergo inhalational induction with sevoflurane in oxygen, followed by maintenance with a volatile agent of the anesthesiologist's choice. In both groups, airway management will be at the discretion of the anesthesiologist. Standard minimum monitoring will be applied. A caudal epidural will then be performed using a standard technique.
Administration of caudal analgesia and whole blood sampling: A caudal dose of 1 ml/kg of 0.25% bupivacaine (2.5 mg/kg) with 1 in 200 000 epinephrine will be administered at time zero (T0). Venous blood samples of 5 ml will be obtained from a second indwelling IV cannula 15 (T1) and 30 (T2) min after caudal injection. These will be collected into EDTA-containing tubes by the PART research assistant and transferred to the BCCH pharmacy research technician (blinded to anesthetic technique) for analysis. Blood samples will be immediately centrifuged. The extracted plasma will be frozen at -850C. Total and free bupivacaine plasma concentrations will be determined using high-pressure liquid chromatography (HPLC) and ultrafiltration.
Data Analysis:
This pilot study will have two primary outcome measures, total and free plasma bupivacaine concentrations. These data will be presented as mean (± SD) at T1 and T2. Normal distribution will be tested by histogram plot. Between-group (TIVA vs. volatile anaesthesia) comparisons of total and free plasma bupivacaine levels will be performed using appropriate analyses of variance. This analysis will determine if there is a detectable difference in plasma concentrations between the TIVA and volatile anaesthesia groups. These data will then be used in a power calculation to determine necessary group sizes for a future randomized controlled trial (RCT) study. Statistical analysis will be conducted using Analyse-It® (Analyse-It Software, Leeds, UK) in consultation with a statistician (Clinical Research Statistical Unit).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- BC Children's Hospital, Department of Anesthesia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age 6 months - 5 years
- ASA I-II
- Undergoing elective day surgery for which combined general and caudal epidural anaesthesia is indicated
- Written parental/guardian informed consent
Exclusion criteria:
- Weight and body mass index < 3rd or > 97th percentile for age
- Any contraindication to caudal injection
- Renal, hepatic, neuromuscular or cardiac disease
- Acute inflammatory process or infectious processes that provoke an acute phase response, ongoing or resolved less than 2 weeks prior to recruitment day (such as recent surgery, respiratory tract infection (including colds), urinary tract infection, infectious or inflammatory gastroenteritis, otitis media, skin or wound infection, cholecystitis, pancreatitis, hepatitis, meningitis) Chronic co-existing inflammatory diseases (eg, inflammatory bowel disease, juvenile arthritis, cystic fibrosis, autoimmune disease, connective tissue disease, chronic liver disease)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: TIVA
|
In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present.
2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard.
Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg.
Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2
mcg/kg/min.
Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples.
This cannula will not be in the same limb as the propofol infusion.
|
Active Comparator: Inhalational
Inhalational/volatile general anesthetic
|
In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air).
Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
Total and free plasma bupivacaine concentrations
|
5 mL blood sample will be obtained at 15 and 30min.
Total and free plasma bupivacaine concentrations
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Simon Whyte, Dr., The University of British Columbia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H10-01501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anesthesia
-
Samsun UniversityCompletedAnesthesia | Regional Anesthesia | Anesthesia ManagementTurkey
-
Charite University, Berlin, GermanyCompletedAnesthesia, Local | Anesthesia | Anesthesia; Adverse EffectGermany
-
Novocol Pharmaceutical of Canada, Inc.CompletedAnesthesia, Local | Dental Anesthesia | Anesthesia, ReversalUnited States
-
Aligarh Muslim UniversityCompletedAnesthesia | Anesthesia Intubation Complication | Anesthesia; Adverse EffectIndia
-
Universitas Sebelas MaretIndonesia Endowment Fund for EducationNot yet recruitingAnesthesia | Anesthesia; Reaction
-
University of PecsCompleted
-
Hormozgan University of Medical SciencesUnknownAnesthesia | Anesthesia; FunctionalIran, Islamic Republic of
-
University of ChicagoRecruitingAnesthesia | Patient Satisfaction | Anesthesia Risks | Anesthesia Consent | Consent RetentionUnited States
-
Assistance Publique - Hôpitaux de ParisINSERM UMR-942, Paris, France; M3DISIMNot yet recruitingPrediction Models for Cardiovascular and Neurocognitive Disease Risk in the General Population (CME)Anesthesia, Local | AnesthesiaFrance
-
Matthew BorzageRecruitingAnesthesia | Anesthesia; ReactionUnited States
Clinical Trials on propofol
-
Hopital FochCompleted
-
Konkuk University Medical CenterCompletedCoronary Artery Disease | Valvular Heart DiseaseKorea, Republic of
-
University Medical Center GroningenCompletedAnesthesia | Hemodynamic Instability | Interaction | Disorder of Oxygen TransportNetherlands
-
Asan Medical CenterCompletedPopulation Pharmacokinetics/Pharmacodynamics (PK/PD) of Microemulsion Propofol in Healthy VolunteersHealthyKorea, Republic of
-
Tiva GroupMedtronic - MITGCompleted
-
Pontificia Universidad Catolica de ChileCompletedSurgery | Anesthesia | Depth of Anesthesia | NeonateChile
-
Mansoura UniversityCompleted
-
KVG Medical College and HospitalUnknown
-
Acibadem UniversityCompleted